McKesson MCK Business Segments
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Business | ||||||
| Medical-Surgical Solutions | $11.51B+0.1% | $11.49B+0.4% | $11.45B0.0% | $11.45B+0.6% | $11.38B+0.2% | |
| North American Pharmaceutical | $336.65B+0.7% | $334.48B+2.2% | $327.35B+2.0% | $320.89B+5.4% | $304.51B+4.0% | |
| Oncology & Multispecialty | $48.42B+7.3% | $45.14B+8.4% | $41.63B+7.5% | $38.74B+5.1% | $36.86B+5.2% | |
| Prescription Technology Solutions | $5.81B+2.8% | $5.65B+2.3% | $5.52B+2.1% | $5.41B+3.7% | $5.22B+3.1% | |
| Subtotal by Business | ||||||
| Medical-Surgical Solutions | $938M+0.5% | $933M-0.4% | $937M+16.0% | $808M+4.3% | $775M-1.5% | |
| North American Pharmaceutical | $3.66B+0.1% | $3.65B+9.3% | $3.34B+17.8% | $2.84B-3.7% | $2.95B+23.9% | |
| Oncology & Multispecialty | $1.15B+7.9% | $1.07B+10.6% | $963M+15.9% | $831M+8.3% | $767M+5.5% | |
| Prescription Technology Solutions | $1.04B+3.8% | $1.01B+4.4% | $964M+4.2% | $925M+5.7% | $875M+4.7% | |
| Total other segment expense, net by Business | ||||||
| Medical-Surgical Solutions | $10.57B+0.1% | $10.56B+0.4% | $10.51B-1.2% | $10.64B+0.3% | $10.61B+0.4% | |
| North American Pharmaceutical | $332.99B+0.7% | $330.82B+2.1% | $324.01B+1.9% | $318.05B+5.5% | $301.56B+3.8% | |
| Oncology & Multispecialty | $47.27B+7.3% | $44.08B+8.4% | $40.66B+7.3% | $37.91B+5.0% | $36.1B+5.2% | |
| Prescription Technology Solutions | $4.76B+2.5% | $4.64B+1.9% | $4.56B+1.6% | $4.48B+3.3% | $4.34B+2.5% | |
| Revenue derived from services (less than) (as a percent) by Business | ||||||
| Prescription Technology Solutions | 118%0.0pp | 118%0.0pp | 118%0.0pp | 118%0.0pp | 118%— | |
| Total segment expenditures for long-lived assets by Business | ||||||
| Medical-Surgical Solutions | $94M-18.3% | $115M-9.4% | $127M-7.3% | $137M-16.0% | $163M-3.4% | |
| North American Pharmaceutical | $334M+9.9% | $304M+7.8% | $282M+2.9% | $274M+12.8% | $243M+22.9% | |
| Oncology & Multispecialty | $78M-11.4% | $88M-10.2% | $98M+4.3% | $94M+6.8% | $88M0.0% | |
| Prescription Technology Solutions | $4M+33.3% | $3M-40.0% | $5M-37.5% | $8M-27.3% | $11M-38.0% | |
| Other by Business | ||||||
| Medical-Surgical Solutions | $2M+33.3% | $1.5M+250% | -$1M+33.3% | -$1.5M+25.0% | -$2M0.0% | |
| Oncology & Multispecialty | $0+100% | -$250K+50.0% | -$500K+33.3% | -$750K+25.0% | -$1M— | |
| Total segment depreciation and amortization by Business | ||||||
| Medical-Surgical Solutions | $96M+1.1% | $95M+3.3% | $92M+1.1% | $91M-1.1% | $92M+4.0% | |
| North American Pharmaceutical | $134M+3.9% | $129M+0.8% | $128M-7.9% | $139M-10.3% | $155M-10.5% | |
| Oncology & Multispecialty | $240M+13.2% | $212M+14.0% | $186M+22.4% | $152M+2.7% | $148M+1.2% | |
| Prescription Technology Solutions | $82M-1.2% | $83M-1.2% | $84M-2.3% | $86M0.0% | $86M0.0% | |
| Foreign currency translation adjustments, net by Business | ||||||
| Medical-Surgical Solutions | $0— | $0— | $0— | $0— | $0— | |
| Prescription Technology Solutions | $0— | $0— | $0— | $0— | $0— | |
| Total reserve balance by Business | ||||||
| Medical-Surgical Solutions | $112M-41.7% | $192M-35.4% | $297M-26.1% | $402M+16.5% | $345M+34.8% | |
| Prescription Technology Solutions | $4M+100% | $2M-50.0% | $4M-50.0% | $8M-33.3% | $12M-25.0% | |
| Other adjustments by Business | ||||||
| Medical-Surgical Solutions | $0-100% | $83M— | —— | —— | —— | |
| Prescription Technology Solutions | -$1M+87.5% | -$8M0.0% | -$8M— | —— | —— | |
| Non-cash charges by Business | ||||||
| Medical-Surgical Solutions | -$8M-142% | $19M+35.7% | $14M0.0% | $14M0.0% | $14M+133% | |
| Prescription Technology Solutions | $17M+143% | $7M0.0% | $7M-12.5% | $8M-11.1% | $9M+350% | |
| Severance and employee-related costs, net by Business | ||||||
| North American Pharmaceutical | $9M— | $0— | $0+100% | -$3M0.0% | -$3M-209% | |
| Restructuring Charges by Business | ||||||
| Medical-Surgical Solutions | $43M-36.8% | $68M-24.4% | $90M-58.7% | $218M+6.9% | $204M+19.3% | |
| North American Pharmaceutical | $24M— | —— | —— | —— | —— | |
| Prescription Technology Solutions | $20M+186% | $7M0.0% | $7M-12.5% | $8M-33.3% | $12M+33.3% | |
| Payments for Restructuring by Business | ||||||
| Medical-Surgical Solutions | $133M-25.3% | $178M-0.6% | $179M+23.4% | $145M+46.5% | $99M+83.3% | |
| Oncology & Multispecialty | $0-100% | $500K-50.0% | $1M-33.3% | $1.5M-25.0% | $2M— | |
| Exit and other-related costs by Business | ||||||
| Medical-Surgical Solutions | $37M-33.9% | $56M-23.3% | $73M+17.7% | $62M+17.0% | $53M+89.3% | |
| North American Pharmaceutical | $3M-40.0% | $5M-16.7% | $6M+50.0% | $4M+33.3% | $3M+300% | |
| Goodwill, transfer to held-for-sale by Business | ||||||
| Medical-Surgical Solutions | $0— | $0— | $0— | —— | —— | |
| Oncology & Multispecialty | $9M+33.3% | $6.75M+50.0% | $4.5M+100% | $2.25M— | $0— | |
| Prescription Technology Solutions | $0— | $0— | $0— | —— | —— | |
| Asset impairments and accelerated depreciation by Business | ||||||
| North American Pharmaceutical | $12M— | —— | —— | —— | —— | |
| Goodwill by Business | ||||||
| Medical-Surgical Solutions | $10.03B0.0% | $10.03B0.0% | $10.03B0.0% | $10.03B-0.3% | $10.06B+0.5% | |
| Prescription Technology Solutions | $8.26B+0.5% | $8.23B+0.5% | $8.18B+0.5% | $8.14B+0.5% | $8.1B0.0% | |
| Goodwill acquired by Business | ||||||
| Medical-Surgical Solutions | $0— | $0— | $0— | —— | —— | |
| Total long-lived assets by Geography | ||||||
| Foreign | $1.1B-4.4% | $1.15B— | —— | —— | —— | |
| United States | $12.35B+2.5% | $12.05B— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does McKesson break its business down?
- McKesson (MCK) reports total revenues by business across 4 parts — Medical-Surgical Solutions, North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions. Each is extracted from the segment footnotes and tracked over time.
- Where does McKesson's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in McKesson's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
